Photo from Yüksel Ürün/X
Apr 7, 2024, 11:45
Yüksel Ürün: Adding immunotherapy to cabozantinib for mccRCC after 1st line immunotherapy showed no extra benefit in real-world data
Yüksel Ürün, Doctorate Professor at the Faculty of Medicine, Ankara University, Turkey, shared a post by ACS Journal Cancer, on X:
“Adding immunotherapy to cabozantinib for metastatic clear cell renal cell carcinoma after 1st line immunotherapy showed no extra benefit in real-world data. This strengthens evidence against re-challenging with immunotherapy after it stopped working. Congrats Georges Gebrael, Neeraj Agarwal, Umang Swami et al.”
Quoting ACS Journal Cancer‘s post:
“Results align with the phase 3 CONTACT-03 trial results, which showed no additional benefit of adding PD-L1 inhibitor to cabozantinib vs cabozantinib alone in 2L following PD-1/L1–based therapies in 1L.”
Read further.
Source: Yüksel Ürün/X and ACS Journal Cancer/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 13:02
Nov 14, 2024, 12:44
Nov 14, 2024, 12:14
Nov 14, 2024, 12:09
Nov 14, 2024, 11:56
Nov 14, 2024, 11:49
Nov 14, 2024, 11:46